Loading...
Loading...
India's ibrutinib imports from UNITED KINGDOM total $84.1K across 4 shipments from 1 foreign suppliers. E PHARM LIMITED leads with $84.1K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include MSN LABORATORIES PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for ibrutinib โ a concentrated sourcing relationship with select suppliers from UNITED KINGDOM.

E PHARM LIMITED is the leading Ibrutinib supplier from UNITED KINGDOM to India, with import value of $84.1K across 4 shipments. The top 5 suppliers โ E PHARM LIMITED โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | E PHARM LIMITED | $84.1K | 4 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MSN LABORATORIES PRIVATE LIMITED | $84.1K | 4 | 100.0% |
UNITED KINGDOM โ India trade corridor intelligence
The United Kingdom to India trade corridor for pharmaceutical imports is currently stable. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion reported. Freight rates have remained consistent over the past year, and the exchange rate between the British Pound and the Indian Rupee has shown moderate fluctuations, not significantly impacting the cost of imports.
The Production Linked Incentive (PLI) scheme has been a key driver in India's push for self-reliance in pharmaceutical manufacturing. While the scheme aims to reduce dependency on imports, it has also led to increased scrutiny of imported formulations, including those containing Ibrutinib. Import substitution policies are being evaluated to encourage domestic production; however, the transition is gradual, and imports continue to play a crucial role in meeting the current demand for specialized formulations.
The trade relationship between India and the United Kingdom has been strengthened through various bilateral agreements, including mutual recognition of Good Manufacturing Practices (GMP) certifications. These agreements have facilitated smoother import processes for pharmaceutical formulations, including those containing Ibrutinib, by reducing regulatory barriers and enhancing trade facilitation.
The landed cost of importing finished Ibrutinib formulations from the United Kingdom to India includes the following components:
The total landed duty percentage, combining BCD, SWS, and IGST, amounts to approximately 32.2%. Per-unit estimates can be calculated by adding the above components to the FOB price, considering the specific quantities and packaging of the formulations.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Ibrutinib into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. The importing company must obtain a valid Importer License from the Directorate General of Foreign Trade (DGFT). Each batch of the formulation must be accompanied by a Certificate of Pharmaceutical Product (CoPP) issued by the manufacturer, ensuring adherence to Good Manufacturing Practices (GMP). The formulation must also be registered with the CDSCO, which involves submitting Form CT-20/40/41, along with stability data demonstrating compliance with International Council for Harmonisation (ICH) guidelines for Zone IV conditions. The registration process typically takes 6 to 12 months, depending on the completeness of the submitted documentation and the CDSCO's evaluation timeline.
Upon arrival in India, each batch of Ibrutinib formulations is subject to quality testing by CDSCO-approved laboratories. The batch must be accompanied by a Certificate of Analysis (CoA) from the manufacturer, detailing the formulation's composition, potency, and compliance with specified standards. Stability data, including accelerated and long-term studies, must be provided to confirm the formulation's shelf-life under Indian climatic conditions. The formulation must meet the standards set forth in the Indian Pharmacopoeia. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported formulations.
Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The Production Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, has led to increased scrutiny of imported formulations, with a focus on encouraging self-reliance. Bilateral agreements between India and the United Kingdom have facilitated smoother trade relations, including mutual recognition of GMP certifications, thereby streamlining the import process for formulations containing Ibrutinib.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Ibrutinib formulations primarily due to the presence of patented or branded formulations not manufactured domestically. Specific dosage forms, such as certain tablet strengths or combination therapies, may not be produced locally, necessitating imports. While India has a robust pharmaceutical manufacturing sector, the demand for imported Ibrutinib formulations indicates a gap in domestic production capabilities for certain specialized products. The market size for Ibrutinib formulations in India is substantial, with imports contributing to a significant portion of the total market value.
The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on the imported value. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is levied. The total landed duty percentage, combining BCD, IGST, and SWS, amounts to approximately 32.2%. Anti-dumping duties are not currently applicable to Ibrutinib formulations. Exemption notifications may apply under specific conditions, such as for formulations intended for government procurement or public health programs.
India sources finished Ibrutinib formulations from the United Kingdom due to the presence of patented formulations and specialized dosage forms not available domestically. The United Kingdom's pharmaceutical industry is known for its high-quality standards and adherence to international regulatory requirements, providing a competitive advantage in the Indian market. Other suppliers, such as China, Germany, and the United States, also export Ibrutinib formulations to India; however, the United Kingdom's share in this segment remains significant due to its established trade relations and product offerings.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Ibrutinib formulations from the United Kingdom due to the availability of patented formulations and specialized dosage forms not produced domestically. The United Kingdom's pharmaceutical industry offers high-quality products that meet international standards, providing a reliable source for formulations containing Ibrutinib. Specific formulations, such as certain tablet strengths or combination therapies, may not be manufactured in India, necessitating imports to meet patient needs.
When compared to other origins like China, Germany, and the United States, the United Kingdom offers a competitive advantage in terms of product quality, regulatory compliance, and established trade relations with India. While other countries may offer lower prices, the United Kingdom's adherence to stringent quality standards and its reputation in the pharmaceutical industry make it a preferred source for formulations containing Ibrutinib.
Indian importers face several supply chain risks when sourcing finished Ibrutinib formulations from the United Kingdom, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to manufacturing issues or regulatory delays; therefore, maintaining a diversified supplier base and robust risk management strategies is essential to mitigate these risks.
Import license checklist, document requirements, quality testing, and compliance
1. DGFT Importer Exporter Code (IEC): Ob
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Ibrutinib suppliers from UNITED KINGDOM to India include E PHARM LIMITED. The leading supplier is E PHARM LIMITED with import value of $84.1K USD across 4 shipments. India imported Ibrutinib worth $84.1K USD from UNITED KINGDOM in total across 4 shipments.
India imported Ibrutinib worth $84.1K USD from UNITED KINGDOM across 4 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Ibrutinib sourced from UNITED KINGDOM include MSN LABORATORIES PRIVATE LIMITED. The largest buyer is MSN LABORATORIES PRIVATE LIMITED with $84.1K in imports across 4 shipments.
The total value of Ibrutinib imports from UNITED KINGDOM to India is $84.1K USD, across 4 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
4 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists